American Society of Hirudotherapy

Knowledge Coverage Map

What ASH covers — and what remains open — across organ systems and evidence tiers.

Last Updated: May 27, 2026ASH Editorial · based on the books
Coverage analytics — institutional reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Auto-updates as registries grow: Content is historical, educational, or biographical reference material — not a clinical recommendation.

ASH organizes its clinical knowledge into structured registries. This page is a live map: as new conditions, compounds, and trials are added, the counts and category distribution update automatically. There are no hand-maintained numbers.

Conditions by evidence tier

174 total conditions across three tiers. Honest framing: most off-label uses are Tier C investigational.

3Tier A: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.

FDA-cleared

K040187: venous congestion in surgical flaps. The only formally FDA-cleared use of medicinal leech therapy.

7Tier B: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.

Off-label with RCT support

Off-label uses with at least one RCT or systematic review. Common candidates: knee OA, chronic venous insufficiency, and certain ENT conditions.

+ 2 more

164Tier C: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.

Investigational

Mechanistic rationale, case series, small pilots. Includes many conditions that mainstream medicine has not researched.

+ 159 more

Coverage by organ system

Links to individual condition pages. Numbers reflect the conditions registry.

Dermatological

36

Tier A: 0 · Tier B: 0 · Tier C: 36

+ 32 more in this category

Neurological

31

Tier A: 0 · Tier B: 0 · Tier C: 31

+ 27 more in this category

What's still open

The 10,000-article target means current coverage is the foundation, not the destination. Major gaps actively being prioritized:

  • Translational pipeline depth: Each compound entry needs detailed drug-development trajectory (preclinical → FDA pathway → clinical context).
  • Pediatric protocols: Limited registry coverage; weight-based dosing absent in current literature.
  • Geographic regulatory survey: Many African, Oceanian, and Caribbean jurisdictions remain "unregulated" — honest marker, but needs ground-truth verification.
  • Recent RCT digestion (2024-2026): Continuous PubMed surveillance for new trials in OA, microsurgery, integrative pain medicine.
  • Translation parity: RU/ES/DE locales need ongoing medical-grade editorial pass across all 37 namespaces.

Researchers and clinicians can contribute via the Contact & Transparency page.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.